A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA)
<strong>Background<br></strong> Approximately one in ten women have high blood pressure during pregnancy. Hypertension is associated with adverse maternal and perinatal outcomes, and as treatment improves maternal outcomes, antihypertensive treatment is recommended. Previous trials...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
BioMed Central
2023
|
| _version_ | 1826311371606720512 |
|---|---|
| author | Ashworth, D Battersby, C Bick, D Green, M Hardy, P Leighton, L Magee, LA Maher, A McManus, RJ Moakes, C Morris, RK Nelson-Piercy, C Sparkes, J Rivero-Arias, O Webb, A Wilson, H Myers, J Chappell, LC |
| author_facet | Ashworth, D Battersby, C Bick, D Green, M Hardy, P Leighton, L Magee, LA Maher, A McManus, RJ Moakes, C Morris, RK Nelson-Piercy, C Sparkes, J Rivero-Arias, O Webb, A Wilson, H Myers, J Chappell, LC |
| author_sort | Ashworth, D |
| collection | OXFORD |
| description | <strong>Background<br></strong>
Approximately one in ten women have high blood pressure during pregnancy. Hypertension is associated with adverse maternal and perinatal outcomes, and as treatment improves maternal outcomes, antihypertensive treatment is recommended. Previous trials have been unable to provide a definitive answer on which antihypertensive treatment is associated with optimal maternal and neonatal outcomes and the need for robust evidence evaluating maternal and infant benefits and risks remains an important, unanswered question for research and clinical communities.
<br><strong>
Methods<br></strong>
The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension. The primary objective is to evaluate if treatment with nifedipine compared to labetalol in women with pregnancy hypertension reduces severe maternal hypertension without increasing fetal or neonatal death or neonatal unit admission. Subgroup analyses will be undertaken by hypertension type (chronic, gestational, pre-eclampsia), diabetes (yes, no), singleton (yes, no), self-reported ethnicity (Black, all other), and gestational age at randomisation categories (11 + 0 to 19 + 6, 20 + 0 to 27 + 6, 28 + 0 to 34 + 6 weeks). A cost-effectiveness analysis using an NHS perspective will be undertaken using a cost-consequence analysis up to postnatal hospital discharge and an extrapolation exercise with a lifetime horizon conditional on the results of the cost-consequence analysis.
<br><strong>
Discussion<br></strong>
This trial aims to address the uncertainty of which antihypertensive treatment is associated with optimal maternal and neonatal outcomes. The trial results are intended to provide definitive evidence to inform guidelines and linked, shared decision-making tools, thus influencing clinical practice.
<br><strong>
Trial registration<br></strong>
EudraCT number: 2020–003410-12, ISRCTN: 12,792,616 registered on 18 November 2020. |
| first_indexed | 2024-03-07T08:07:19Z |
| format | Journal article |
| id | oxford-uuid:eb42ed6e-1b20-4a99-8ea7-33ef28a3a5b7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:07:19Z |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:eb42ed6e-1b20-4a99-8ea7-33ef28a3a5b72023-11-07T15:48:44ZA treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:eb42ed6e-1b20-4a99-8ea7-33ef28a3a5b7EnglishSymplectic ElementsBioMed Central2023Ashworth, DBattersby, CBick, DGreen, MHardy, PLeighton, LMagee, LAMaher, AMcManus, RJMoakes, CMorris, RKNelson-Piercy, CSparkes, JRivero-Arias, OWebb, AWilson, HMyers, JChappell, LC<strong>Background<br></strong> Approximately one in ten women have high blood pressure during pregnancy. Hypertension is associated with adverse maternal and perinatal outcomes, and as treatment improves maternal outcomes, antihypertensive treatment is recommended. Previous trials have been unable to provide a definitive answer on which antihypertensive treatment is associated with optimal maternal and neonatal outcomes and the need for robust evidence evaluating maternal and infant benefits and risks remains an important, unanswered question for research and clinical communities. <br><strong> Methods<br></strong> The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension. The primary objective is to evaluate if treatment with nifedipine compared to labetalol in women with pregnancy hypertension reduces severe maternal hypertension without increasing fetal or neonatal death or neonatal unit admission. Subgroup analyses will be undertaken by hypertension type (chronic, gestational, pre-eclampsia), diabetes (yes, no), singleton (yes, no), self-reported ethnicity (Black, all other), and gestational age at randomisation categories (11 + 0 to 19 + 6, 20 + 0 to 27 + 6, 28 + 0 to 34 + 6 weeks). A cost-effectiveness analysis using an NHS perspective will be undertaken using a cost-consequence analysis up to postnatal hospital discharge and an extrapolation exercise with a lifetime horizon conditional on the results of the cost-consequence analysis. <br><strong> Discussion<br></strong> This trial aims to address the uncertainty of which antihypertensive treatment is associated with optimal maternal and neonatal outcomes. The trial results are intended to provide definitive evidence to inform guidelines and linked, shared decision-making tools, thus influencing clinical practice. <br><strong> Trial registration<br></strong> EudraCT number: 2020–003410-12, ISRCTN: 12,792,616 registered on 18 November 2020. |
| spellingShingle | Ashworth, D Battersby, C Bick, D Green, M Hardy, P Leighton, L Magee, LA Maher, A McManus, RJ Moakes, C Morris, RK Nelson-Piercy, C Sparkes, J Rivero-Arias, O Webb, A Wilson, H Myers, J Chappell, LC A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title_full | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title_fullStr | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title_full_unstemmed | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title_short | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA) |
| title_sort | treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension study protocol for a randomised controlled trial giant panda |
| work_keys_str_mv | AT ashworthd atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT battersbyc atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT bickd atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT greenm atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT hardyp atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT leightonl atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mageela atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mahera atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mcmanusrj atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT moakesc atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT morrisrk atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT nelsonpiercyc atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT sparkesj atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT riveroariaso atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT webba atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT wilsonh atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT myersj atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT chappelllc atreatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT ashworthd treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT battersbyc treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT bickd treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT greenm treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT hardyp treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT leightonl treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mageela treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mahera treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT mcmanusrj treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT moakesc treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT morrisrk treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT nelsonpiercyc treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT sparkesj treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT riveroariaso treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT webba treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT wilsonh treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT myersj treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda AT chappelllc treatmentstrategywithnifedipineversuslabetalolforwomenwithpregnancyhypertensionstudyprotocolforarandomisedcontrolledtrialgiantpanda |